Tolerability of 3-day, once-daily azithromycin suspension versus standard treatments for community-acquired paediatric infectious diseases

Authors: Treadway G.¹; Reisman A.

Source: International Journal of Antimicrobial Agents, Volume 18, Number 5, November 2001 , pp. 427-431(5)

Publisher: Elsevier

Keywords: Azithromycin; Safety; Paediatric; Macrolide; beta -Lactam; Infectious diseases

Language: English

Document Type: Research article

DOI: 10.1016/S0924-8579(01)00439-3

Affiliations: 1: Pfizer Pharmaceuticals Group, Pfizer Inc., 235 East 42nd Street, 10017-5755, New York, NY, USA

Links for this article

http://www.ingentaconnect.com/els/09248579/2001/00000018/00000005/art00439
http://openurl.ingenta.com/content?genre=article&issn=0924-8579&volume=18&issue=5&spage=427&epage=431
http://dx.doi.org/10.1016/S0924-8579(01)00439-3